Completed
OBSERVATIONAL
NCT02139410
IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.
Interventions
Name:
IGF-1 serum value
Type:
PROCEDURE
Description:
Evaluation of IGF-1 serum value at baseline, 24 and 48 months
Primary Outcomes
Measure:
IGF-1 reduction in patients with sarcopenia
TimeFrame:
baseline, 24 months, 48 months
Description:
IGF-1 reduction could be linked to sarcopenia in patients with cognitive impairment
Trial Information
NCT ID
NCT02139410
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
University of Roma La Sapienza
Last Updated
December 15, 2025